About Us

VSCP is a strategic private equity investor with expertise in healthcare services.

VSCP is a strategic private equity manager with substantial and differentiated Healthcare Services sector and sourcing expertise.  Specifically, we specialize in middle market buyouts and growth equity investments, with a focus on businesses with strong cash flow characteristics that create value for hospitals and physicians by enhancing efficiency, improving quality, reducing costs and expanding revenues.  Since inception, the firm has deployed nearly $400 million in capital, primarily as a control investor.

Credit: HLM


Founded in 2014, the firm's partners trace a history together of over 20 years. The team cut its teeth for many years at Lehman Brothers, and eventually transitioned to lead M&A and Strategy efforts at several of the country's largest Healthcare organizations. Over that time, they built C-Suite relationships at many of Corporate America's most successful Healthcare Services organizations. After successfully creating an internal private equity vehicle at LabCorp, the largest clinical diagnostic company in the U.S., Adam Feinstein launched Vesey Street Capital Partners. The fund made its initial investment in ScribeAmerica within 60 days of formation.


With over 50 combined years of analyzing and investing in Healthcare Services companies, and with an experienced and prestigious advisory board, VSCP possesses unparalleled industry knowledge and expertise. Collectively the team has worked with hundreds of Healthcare companies and developed lasting relationships with industry executives and luminaries, which serve as the foundation for our deal sourcing strategy.

Investment Philosophy

The U.S. Healthcare system is currently experiencing unprecedented change, which has led to tremendous uncertainty across the sector. However, we believe this will lead to significant opportunities to create future value. Fundamentally, we favor middle market companies that can provide services to hospitals, physician groups, and payors, which reduce costs, enhance efficiency, drive quality and build scale.

Investment Criteria

  • We invest in U.S. middle-market buyouts and growth equity transactions
  • We prefer founder-led and corporate carve-out businesses
  • Targeted EBITDA of $10-25 million, with the ability to scale significantly higher
  • We focus on investments that meet our overall firm strategy, rather than check size
  • Actively investing in both control and co-investment opportunities, with preference for control transactions